Novel Inhibitors of the Androgen Receptor for the Treatment of Castration Resistant Prostate Cancer (CRPC)

Case ID:

This invention is a new class of heterocyclic small-molecules designed to antagonize the androgen receptor. These molecules have promising biological activity in a prostate specific cell line.



The primary method for treating early stage prostate cancer is via androgen deprivation therapy because prostate cancer needs androgen in order to fuel growth. However, this form of therapy is sub-par because the tumor can develop a method to circumvent the need for large quantities of androgen by simply adding more androgen receptors. A new method of treatment is needed in order to better treat prostate cancer. 



  • Targets receptor and not the hormone itself
  • Several variation of molecules, giving a wide variety of mechanisms for the antagonizing effect
  • Effects are targeted, leading to predictable and preventable side effects



  • Treatment of prostate cancer
  • Slowing the progression of prostate cancer
  • Combination therapy to be utilized with other prostate cancer therapies


Patent Information: Provisional Patent Application Filed

Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Christopher Hulme
Yeng Jeng Shaw
Vijay Gokhale